LGVN News and Press, Longeveron Inc. From 03/12/21

Marker Therapeutics MRKR -24% after prices stock offering.Timber Pharmaceuticals (TMBR) -25%.Evoke Pharma EVOK -24% on Q4 earnings release.FinVolution (FINV) -15%.Poshmark POSH -15% on Q4 earnings release; after Q1 revenue guidance falls short.AMMO POWW ...

Longeveron Inc. (LGVN) has surged ~45.5% in the premarket after the company announced that the FDA has granted approval for its experimental therapy Lomecel-B on a compassionate use basis to treat a child with Hypoplastic Left Heart Syndrome (“HLHS”).An allog...

MIAMI, March 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administration ...

MIAMI, March 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the Company has expanded and amended its...

Longeveron (LGVN) announces that the enrollment criteria for its Phase 1 Acute Respiratory Distress Syndrome ((ARDS)) RECOVER trial has been expanded to include mild ARDS, in addition to moderate and severe ARDS caused by COVID-19 or Influenza Infection.The protocol amendment allows for ...

MIAMI, March 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that enrollment criteria for its Phase 1 Acut...

Trial funded in part by a National Institute on Aging Small Business Innovation Research (SBIR) Grant Trial objectives include evaluation of Lomecel-B’s effect on physical function, mobility, strength, balance, endurance, fear and risk of falling, inflammatory biomarker...

Longeveron (LGVN) announces completion of its Phase 1 clinical study of Lomecel-B in Hypoplastic Left Heart Syndrome ((HLHS)), a rare congenital heart defect that effects about 1,000 babies per year in the U.S.Shares up nearly 8% premarket.Lomecel-B is an allogeneic, bone ...

Intramyocardial injection of Lomecel-B well-tolerated, with no major cardiac events, and no serious adverse events related to Lomecel-B reported Full results of the Phase 1 clinical trial expected to be released in Q2 2021 Phase 2 trial expected to commence in Q3 2021 ...

MIAMI, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, Chief Executive Officer of L...